Most Popular
Breaking News
Newsletter
Cyagen and Biointron Announce Strategic Alliance to Advance Antibody Drug Discovery
Mar 28, 2024
Cyagen Biosciences (Suzhou) Inc. (“Cyagen Biosciences”) and Shanghai BaiYing Bio-Technology Co., Ltd. (“Biointron”) have signed a strategic cooperation agreement. This partnership aims to fully leverage the advantages of Cyagen Biosciences' antibody discovery platform, featuring next-generation HUGO-Ab™ Fully Humanized Antibody Mice, in combination with the strengths of Biointron's Single B Cell Screening Antibody Discovery platform for developing antigen-specific monoclonal antibodies (mAbs). Read More >
Newsletter
Breaking News
Cyagen Congratulates Our Partner INNOVEC on Receiving FDA Pediatric Rare Disease Designation (RPDD) for IVB102 Injection
Jan 23, 2024
The United States Food and Drug Administration (FDA) granted Beijing InnoVec Biotherapeutics’ InnoVex IVB102 injection the Rare Pediatric Disease Designation (RPDD) on January 10, 2024. Innovec is now one step closer to being eligible for the Rare Pediatric Disease Priority Review Voucher (PRV) for the treatment of rare pediatric diseases with the InnoVex IVB102 injection in the United States. Read More >
Breaking News
Newsletter
HistoWiz and Cyagen Collaborate to Streamline Histopathology for Academic and Preclinical Mouse and Rat Model Research
Oct 23, 2023
SALT LAKE CITY, Utah–AALAS 2023–Booth #2717– (October 23, 2023)--HistoWiz, a leading provider of histology and slide archiving services, and Cyagen Biosciences, an AI-enabled CRO company specializing in custom genetically engineered animal and cell models for research, announced today at the American Association for Laboratory Animal Science (AALAS) a strategic co-marketing partnership to streamline histopathology services. Read More >
Breaking News
YIMA and ZIP Solutions Announce Strategic Co-Marketing Agreement for Gene Therapy
Jun 08, 2023
ZIP Solutions (Barcelona), a 100% affiliate of Biat Group (ticker BST), and YIMA Gene, a subsidiry under Cyagen Group, are please to announce a strategic co-marketing agreement for gene therapy. Read More >
Breaking News
Newsletter
Cyagen and Landau Strengthen Cooperation to Accelerate the Research and Development of AI-designed AAV Gene Therapy Vectors
Dec 12, 2022
Recently, Cyagen and Guangdong Landau Biotechnology Co., Ltd. (hereinafter referred to as "Landau Biotech") strengthened their strategic partnership on the basis of the original strategic cooperation. Read More >
Video
Newsletter
Breaking News
Q&A
The First Artificial Chief Scientific Officer: AI Marvin
Nov 21, 2022
Have you ever wondered what the future of science education looks like? Many envision a future of readily accessible science knowledge and facts presented by intelligent, interactive teachers. Read More >
Breaking News
Cyagen and Neurophth Enter Global Strategic Collaboration to Develop AI-Designed AAV Gene Therapy Vectors for Ophthalmic Disorders
Nov 08, 2022
Cyagen today announced a strategic collaboration with Neurophth Therapeutics, Inc. to co-develop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders. Read More >
Newsletter
Breaking News
Taconic-Cyagen Custom Animal Model Awards (CAMA) Announces 6 Winners
May 14, 2021
We are delighted to announce the winners of the first Taconic-Cyagen Custom Animal Model Awards (CAMA) competition. Read More >
Newsletter
Breaking News
Rare Disease Day 2021 – Achieving Equity
Feb 26, 2021
With over 300 million people worldwide living with a rare disease, Rare Disease Day aims to raise awareness of what it means to be rare. On the last day of February each year, the Rare Disease community comes together to work toward more equitable access to diagnosis, treatment, care, and social opportunity for people with a rare disease. Read More >
Newsletter
Breaking News
Conditional Knockout (Floxed) Mice Now Available from Cyagen Knockout Catalog Models
Oct 19, 2020
In March 2020, Cyagen officially launched the Cyagen Knockout Catalog Models repository – which has provided researchers in the Americas and Europe with ready to use knockout (KO) mouse models in as few as three (3) months. To date, we have cryopreserved sperm from over 10k KO mouse strains to offer affordable, established, and rapidly available KO models to both research institutions and pharmaceutical corporations. Read More >